Nandrolone Decanoate

ID: nandrolone_decanoate

Aliases: nandrolone, Deca-Durabolin, Deca

Type: compound

Route/form: intramuscular injection

Status: approved_or_legacy_prescription

Evidence level: approved / labelled

Best data tier: approved label + human controlled/review

Support scope: human, review/regulatory

Source types: human_rct, label, meta_analysis, review, safety_review, systematic_review

Linked sources: 8

Broad outcomes: Fat loss / metabolic health, Hormones / fertility / sexual health, Muscle growth / performance / recovery, PEDs / AAS / thermogenics, Safety / regulatory

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• androgen receptor agonist
• 19-nortestosterone derivative
• HPG-axis suppression

Optimization domains

• steroid
• muscle
• body composition
• cachexia
• anemia
• androgen therapy
• fertility
• doping

Research basis

• Label and human RCT evidence support anabolic effects in specific catabolic, burn, anemia, or bone contexts.
• Compound-specific reviews and randomized evidence make nandrolone a central reference for separating therapeutic anabolic steroid use from nonmedical enhancement.
• It is a useful comparator because it is a real prescription/legacy AAS with meaningful human data, not a purely gray-market research chemical.

Limits, risks, and missing evidence

• Nonmedical use inherits AAS-class suppression, fertility, lipid, blood-pressure, cardiac, androgenic, and psychiatric risks.
• Disease-wasting, burn, anemia, and osteoporosis data do not automatically translate to healthy strength or physique cycles.
• Preclinical behavioral-alteration literature and AAS cardiovascular reviews argue against treating nandrolone as merely mild or joint-friendly.

Risk flags

• prescription or legacy context
• endocrine suppression
• fertility risk
• cardiovascular risk
• neuropsychiatric risk
• doping

Linked papers, labels, and reviews

1. DailyMed label: Nandrolone decanoate injection
   label / dailymed_nandrolone_decanoate_label
   Official nandrolone decanoate label; anchors approved anemia context, IM route, androgen risks, and controlled-drug framing.
2. Anabolic effects of nandrolone decanoate in patients receiving dialysis: a randomized controlled trial
   human_rct / jama_nandrolone_dialysis_rct_1999
   Direct human RCT in dialysis patients; supports disease-associated wasting/anabolic effects, not nonmedical cycling.
3. Anabolic-androgenic steroids: How do they work and what are the risks?
   review / pubmed_aas_risks_2023
   General AAS mechanism and risk review; used as class-level caution for nonmedical androgen/anabolic steroid entries.
4. Nandrolone Decanoate: Use, Abuse and Side Effects
   review / pubmed_nandrolone_use_abuse_side_effects_2020
   Compound-specific nandrolone review covering therapeutic uses, abuse patterns, and adverse effects.
5. Nandrolone decanoate safely combats catabolism in burned patients: A new potential indication after recall
   human_rct / pubmed_nandrolone_burns_rct_2021
   Human burn-catabolism trial context for nandrolone; disease/injury setting rather than healthy enhancement.
6. Nandrolone Decanoate for Postmenopausal Osteoporosis: A Systematic Review and Meta-Analysis of Randomized Trials
   meta_analysis / pubmed_nandrolone_osteoporosis_meta_2025
   Randomized-trial evidence synthesis in postmenopausal osteoporosis; useful for bone/anabolic clinical context and adverse-effect framing.
7. Association between nandrolone and behavioral alterations: A systematic review of preclinical studies
   systematic_review / pubmed_nandrolone_behavior_preclinical_review_2021
   Preclinical behavioral-risk synthesis for nandrolone; useful neuropsychiatric caution source.
8. Anabolic-androgenic steroids among recreational athletes and cardiovascular risk
   safety_review / pubmed_aas_recreational_athletes_cv_review_2025
   Recent cardiovascular-risk review focused on recreational athlete AAS use; class-level safety source for nonmedical androgen entries.